

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number  
**WO 2005/082893 A3**

(51) International Patent Classification<sup>7</sup>: **C07D 295/12**,  
295/06, 295/02

(21) International Application Number:  
PCT/US2005/005491

(22) International Filing Date:  
22 February 2005 (22.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/547,758 25 February 2004 (25.02.2004) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEAVERS, Lisa**, Selsam [US/US]; 74 North Edwards Street, Franklin, Indiana 46131 (US). **GADSKI, Robert, Alan** [US/US]; 4431 North Illinois, Indianapolis, Indiana 46208 (US). **HIPSKIND, Philip, Arthur** [US/US]; 4255 Cabin Court, New Palestine, Indiana 46163 (US). **JESUDASON, Cynthia, Darshini** [US/US]; 1090 Fleetwood Drive, Indianapolis, Indiana 46228 (US). **LINDSLEY, Craig, William** [US/US]; 4349 Annandale Road, Schwenksville, Pennsylvania 19473 (US). **LOBB, Karen, Lynn** [US/US]; 7358 Windsor Lakes Place, Indianapolis, Indiana 46237 (US). **PICKARD, Richard, Todd** [US/US]; 20980 Prairie Baptist Road, Noblesville, Indiana 46060 (US).

(74) Agents: **WOOD, Dan, L.** et al.; P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))


**Published:**

- with international search report

(88) Date of publication of the international search report:  
20 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES



(57) Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity and other histamine H3 receptor -related diseases.

WO 2005/082893 A3